文献速递肝病

LGP2 Q425R变异降低欧洲慢性丁型肝炎患者肝病严重程度

Carriage of the Laboratory of Genetics and Physiology Protein 2 Q425R Variant Reduces Liver Disease Severity in European Patients With Chronic Hepatitis Delta.
PubMed 文献 · Aliment Pharmacol Ther · 2026-09-17

本研究纳入192例未治疗的慢性丁型肝炎患者,检测LGP2 rs2074158 T>C基因型,评估Q425R变异与肝病严重程度的关系。结果显示Q425R携带者肝硬化患病率更低(60.7% vs. 76.3%,p=0.025),血小板计数更高(152 vs. 116 × 10^3/μL,p=0.022)。多因素分析表明Q425R携带与较低肝硬化率独立相关(p=0.003)。

要点

  • Q425R携带者肝硬化患病率显著低于野生型(60.7% vs. 76.3%)。
  • Q425R携带者血小板计数更高(152 vs. 116 × 10^3/μL)。
  • Q425R携带是较低肝硬化率的独立相关因素(p=0.003)。

核心结论

  • LGP2 Q425R变异与欧洲未治疗慢性丁型肝炎患者肝硬化风险降低独立相关。

研究设计与样本

  • 研究纳入192例未治疗的慢性丁型肝炎患者,进行LGP2 rs2074158 T>C基因分型,以组织学或肝脏硬度测定评估肝纤维化,采用多因素logistic回归分析变异与临床参数的关系。

主要发现

  • Q425R携带者肝硬化患病率为60.7%,野生型为76.3%(p=0.025)。
  • Q425R携带者血小板计数为152 × 10^3/μL,野生型为116 × 10^3/μL(p=0.022)。
  • Q425R携带(p=0.003)、较年轻年龄(p=0.004)和较低血清胆汁酸水平(p=0.029)与较低肝硬化率独立相关。
  • Q425R患病率随肝脏硬度值升高而降低:LSM≤6.2 kPa为50%,>6.2且≤12 kPa为41%。
  • Q425R患病率随血小板计数降低而降低:PLT≥150为33.3%,≥100且<150为29.3%,≥50且<100为24.5%,<50 × 10^9/L为18.8%(p=0.011)。

关键数值与推荐

  • 肝硬化定义为肝脏硬度测定>12 kPa,门静脉高压定义为血小板减少。
  • LGP2野生型为TT基因型,Q425R变异为CC/CT基因型。

临床怎么用

  • 对于慢性丁型肝炎患者,可考虑检测LGP2 Q425R变异以辅助评估肝硬化风险。
  • Q425R携带者可能具有较好的肝病预后,需结合年龄、胆汁酸水平和血小板计数综合判断。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Laboratory of genetics and physiology protein 2 (LGP2) Q425R variant enhances interferon-mediated antiviral responses in chronic hepatitis delta (CHD) in vitro. This study aimed to evaluate the association between the LGP2 Q425R variant and liver disease severity in untreated CHD patients. METHODS: In total, 192 patients with CHD were studied. LGP2 rs2074158 T>C genotyping was performed to identify the LGP2 wild-type (WT, TT genotype) and Q425R (CC/CT genotypes) variants. Liver fibrosis was evaluated by histology or liver stiffness measurement (LSM). Cirrhosis was defined by LSM > 12 kPa, and portal hypertension by thrombocytopenia. Associations between LGP2 WT and Q425R variants and clinical parameters were assessed using multivariate logistic regression analysis. RESULTS: LGP2 WT and Q425R were detected in 68.2% and 31.8% of the patients, respectively. Q425R carriers showed a lower prevalence of cirrhosis (60.7% vs. 76.3%, p = 0.025) and higher platelet (PLT) counts (152 vs. 116 × 103/μL, p = 0.022). Q425R carriage (p = 0.003), younger age (p = 0.004), and lower serum bile acid levels (p = 0.029) were independently associated with lower cirrhosis rates. Q425R prevalence progressively decreased from 50% to 41% in patients with LSM values ≤ 6.2 kPa and > 6.2 ≤ 12 kPa and from 33.3% to 29.3% to 24.5% to 18.8% in cirrhotic patients with PLT ≥ 150, ≥ 100 < 150, ≥ 50 < 100 and < 50 × 109/L, respectively, (p = 0.011). CONCLUSIONS: The LGP2 Q425R variant is independently associated with a reduced risk of cirrhosis in European untreated patients with CHD. These results confirm in vivo that enhanced host innate immune responses modulate the natural history of CHD in vivo.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Cmet S, Degasperi E, Cussigh A, et al. Carriage of the Laboratory of Genetics and Physiology Protein 2 Q425R Variant Reduces Liver Disease Severity in European Patients With Chronic Hepatitis Delta. Aliment Pharmacol Ther. 2026. PMID: 42753128. doi:10.1111/apt.70971

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。